CorMedix Licenses New Technology to Prevent Infection and Clots in Central Venous Catheters
SUMMIT, N.J., Feb. 6, 2008 (PRIME NEWSWIRE) -- CorMedix Inc., a New York-area biopharmaceutical company, announced today that it had acquired exclusive worldwide rights to develop, manufacture and market Neutrolin(r), a liquid that "locks" a patient's central venous catheter (CVC) between hemodialysis (HD) sessions to keep it free of infection and clots.